Voranox Vitae
The clinical co-pilot for the next century of medicine.
A preview of the bedside surface a Vitae clinician uses — patient synthesis, evidence, and the artifact a tumor board actually convenes around.
Patient · 2418-EH
67F · Post-op day 2 · CABG ×3
Cardiothoracic ICU · admitted 2 days ago
HR
78
bpm
—
BP
118 / 72
mmHg
↘ 4
SpO₂
97%
—
Temp
37.4
°C
↗ 0.3
Synthesis · Last 24 hours
Co-pilot summary
Hemodynamics
Stable on minimal inotropic support; weaned to dobutamine 2.5 mcg/kg/min overnight.
Renal
UO 0.8 mL/kg/hr × 6h; Cr 1.4 (↑0.2 from baseline). Consider fluid balance review.
Electrolytes
K+ 5.4 (↑); recheck after 1 dose K-binder. Mg 1.9. Repeat panel in 4h.
Pulmonary
Extubated POD 1; on 2L NC; SpO₂ 97%. CXR clear, no effusion.
Pain & Mobility
Pain 3/10 on PCA morphine. Up to chair this morning. PT consult requested.
Evidence · Cited
Source provenance
K+ binder appropriate for K+ 5.4 in post-op CABG
Wean dobutamine prior to extubation if MAP > 65
UO < 0.5 mL/kg/hr × 6h: AKI stage 1 trigger
Early mobilization within 48h reduces POD
PCA morphine appropriate; consider taper from POD 3
Recommendations · Pending Clinician Review
Awaiting attending
Recheck BMP in 4 hours
K+ trending up; verify response to K-binder and inform repeat dose decision.
Initiate fluid balance review
UO marginal × 6h; Cr trending. Stage 1 AKI risk.
PT consult — early mobilization
POD 2; ERAS protocol supports activity progression.
Begin opioid taper plan POD 3
Pain controlled; multi-modal analgesia per ERAS Cardiac.
Governance in force
Illustrative preview. Patient data is synthetic; clinical content is non-operational example.
Engage Vitae
For the institutions ready to give clinicians more time.
Vitae is in private engagement with academic medical centers and integrated delivery networks. Briefings are available to qualified clinical leadership under NDA.
Request a Confidential Briefing